Business Wire

Partnership for Sustainable Textiles Recognizes U.S. Cotton Trust Protocol as a Standard for Sustainable Cotton

13.6.2022 15:32:00 EEST | Business Wire | Press release

Share

The U.S. Cotton Trust Protocol has been approved as a standard for sustainable cotton by Siegelklarheit, an initiative of the German Federal Government. By helping consumers to better understand environmental and social labels, Siegelklarheit wants to contribute to more sustainable purchasing decisions. U.S. Cotton Trust Protocol successfully passed Siegelklarheit´s assessment system. As a result, members of the Partnership for Sustainable Textiles (PST) can use the Trust Protocol as another standard to calculate their share of sustainable cotton.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005297/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

U.S. Cotton Trust Protocol (Photo: Business Wire)

The Partnership for Sustainable Textiles was founded in October 2014, with the mission to improve social and ecological conditions within global textile supply chains. The Textiles Partnership orientates its work on the OECD Due Diligence Guidance and on international agreements and guidelines that define the principles of social, environmental, and economic sustainability and the framework for corporate responsibility.

“Members of the Partnership for Sustainable Textiles work together to achieve substantial social and ecological improvements in their global supply chains,” said Jürgen Janssen, head of the PST secretariat. “This also includes the production of raw materials and thus the cultivation and processing of cotton. In the Textiles Partnership, we advocate for transparent and traceable criteria in the certification of sustainable cotton. We are pleased that the Trust Protocol has successfully passed the audit by Siegelklarheit.”

The PST has developed an implementation framework and reporting format for corporate due diligence. In the context of this format PST member companies also indicate how much cotton they source and how much of it is sustainable or organic cotton, certified by recognized standards. Besides U.S. Cotton Trust Protocol, these include Better Cotton standard, the Australian myBMP standard, Cotton made in Africa, Fairtrade Cotton and CottonConnect. The following standards apply to purchasing of organic cotton: the Global Organic Textile Standard (GOTS), the International Association of Natural Textile Industry (NATURTEXTIL IVN) standard, the Textile Exchange Organic Content Standard (OCS), the bioRe Social & Environmental Standard, and all the organic standards forming part of the IFOAM Family of Standards.

The Trust Protocol is the only system that provides quantifiable, verifiable goals and measurement and drives continuous improvement in six key sustainability metrics - land use, soil carbon, water management, soil loss, greenhouse gas emissions, and energy efficiency. It is also the world’s first sustainable cotton fiber to offer its members article-level supply chain transparency through the Protocol Consumption Management Solution.

“We are thrilled to have received this recognition of being a sustainable cotton standard by the Partnership for Sustainable Textiles and proud to have passed Siegelklarheit’s rigorous assessment,” said Dr. Gary Adams, president of the U.S. Cotton Trust Protocol. “The Trust Protocol’s vision is to set a new standard in sustainable cotton production where full transparency is a reality and continuous improvement to reduce our environmental footprint is the central goal. We commit to ensuring the protection and preservation of the planet, using the most sustainable and responsible techniques.”

The U.S. Cotton Trust Protocol is aligned with the UN Sustainable Development Goals, recognized by Textile Exchange and Forum for the Future, and part of the Sustainable Apparel Coalition, Cotton 2025 Sustainable Cotton Challenge, Cotton 2040 and Cotton Up initiatives. It has also been recognized and published in the ITC Standards Map.

To learn more about the U.S. Cotton Trust Protocol visit TrustUSCotton.org.

About the U.S. Cotton Trust Protocol

Launched in 2020, the U.S. Cotton Trust Protocol was designed to set a new standard in more sustainably grown cotton, ensuring that it contributes to the protection and preservation of the planet, using the most sustainable and responsible techniques. It is the only farm level, science-based program that provides quantifiable, verifiable goals and measurement in six key sustainability metrics as well as article-level supply chain transparency.

The Trust Protocol is overseen by a multi-stakeholder Board of Directors comprised of representatives from brands and retailers, civil society, and independent sustainability experts as well as the cotton-growing industry, including growers, ginners, merchants, wholesalers and cooperatives, mills, and cottonseed handlers.

About the Partnership for Sustainable Textiles

The Partnership for Sustainable Textiles (PST) is committed to a socially, ecologically, and corruption-free textile and garment industry – an industry that respects the rights of all workers, that protects the climate and the environment, and operates with integrity and within planetary boundaries. The Textiles Partnership aligns its work on international agreements and guidelines that define the principles of social, environmental, and economic sustainability and set the framework for corporate responsibility. The objectives of the PST concerning social and human rights issues are based in particular on the ILO Conventions, the UN Principles on Business and Human Rights, and the OECD Guidelines for Multinational Enterprises. In implementing its goals, the Partnership is strongly oriented towards the recommendations of the OECD. In order to achieve its goals, the PST places a special focus on the implementation of corporate due diligence and responsible business conduct in Germany, Europe and worldwide.

Website: https://www.textilbuendnis.com/en

Visit us online at TrustUSCotton.org.

Follow us at:
https://twitter.com/trustuscotton
https://www.facebook.com/trustuscotton/
https://www.instagram.com/trustuscotton/
https://www.linkedin.com/company/responsibleuscotton/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media: Andrea Miles, andrea.miles@hkstrategies.com, +1 (213) 400-8267

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye